Certara Reports Fourth Quarter and Full Year 2021 Financial Results
01 mars 2022 16h15 HE
|
Certara
PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021...
U.S. FDA Licenses Certara’s Immunogenicity Simulator
23 févr. 2022 16h30 HE
|
Certara
PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed...
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year
15 févr. 2022 16h30 HE
|
Certara
PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...
Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022
08 févr. 2022 16h30 HE
|
Certara
PRINCETON, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and...
Insights on the Biosimulation Global Market to 2026 - Featuring Certara, Evidera and Gendata Among Others
06 janv. 2022 03h58 HE
|
Research and Markets
Dublin, Jan. 06, 2022 (GLOBE NEWSWIRE) -- The "Biosimulation Market Research Report by Product & Service, Delivery Model, End-user, Application, and Region - Global Forecast to 2026 - Cumulative...
Global Biosimulation Market Research Report 2021-2028 - Surging Demand for Biosimulation Software & Services due to their Higher Cost-Efficiency
30 déc. 2021 07h48 HE
|
Research and Markets
Dublin, Dec. 30, 2021 (GLOBE NEWSWIRE) -- The "Global Biosimulation Market Size, Share & Trends Analysis Report by Product (Software, Services), by Application (Drug Development, Drug...
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
21 déc. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and...
Certara Announces Release of Pinnacle 21 Enterprise Software
13 déc. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates...
Certara to Host Investor Day on December 15, 2021
08 déc. 2021 17h00 HE
|
Certara
PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM...
Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances
02 déc. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 21, which updates the...